Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016

Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016
Published Jul 13, 2016
60 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016, provides an overview of the Charcot-Marie-Tooth Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease
- The report reviews pipeline therapeutics for Charcot-Marie-Tooth Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Charcot-Marie-Tooth Disease therapeutics and enlists all their major and minor projects
- The report assesses Charcot-Marie-Tooth Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Charcot-Marie-Tooth Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measure

  
Source:
Document ID
GMDHC8265IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Charcot-Marie-Tooth Disease Overview71
Therapeutics Development82
  Pipeline Products for Charcot-Marie-Tooth Disease Overview81
  Pipeline Products for Charcot-Marie-Tooth Disease Comparative Analysis91
Charcot-Marie-Tooth Disease Therapeutics under Development by Companies101
Charcot-Marie-Tooth Disease Therapeutics under Investigation by Universities/Institutes111
Charcot-Marie-Tooth Disease Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Charcot-Marie-Tooth Disease Products under Development by Companies141
Charcot-Marie-Tooth Disease Products under Investigation by Universities/Institutes151
Charcot-Marie-Tooth Disease Companies Involved in Therapeutics Development168
  Acetylon Pharmaceuticals, Inc.161
  Addex Therapeutics Ltd171
  Affectis Pharmaceuticals AG181
  Genzyme Corporation191
  InFlectis BioScience201
  Lead Discovery Center GmbH211
  PharmatrophiX, Inc.221
  Pharnext SAS231
Charcot-Marie-Tooth Disease Therapeutics Assessment249
  Assessment by Monotherapy Products241
  Assessment by Combination Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration301
  Assessment by Molecule Type312
Drug Profiles3314
  (baclofen + naltrexone + sorbitol) Drug Profile332
  ADX-71441 Drug Profile353
  AFC-5128 Drug Profile381
  IFB-088 Drug Profile391
  LM-22B10 Drug Profile401
  Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Drug Profile411
  Small Molecule to Inhibit Rab7 GTPase for Oncology, Neuropathy, Immunology, Neurodegenerative Diseases, Lipidoses and Charcot-Marie-Tooth Disease Type II Drug Profile421
  Small Molecules for Charcot-Marie-Tooth Disease Type I A Drug Profile431
  Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders Drug Profile441
  Small Molecules to Inhibit PMP22 for Charcot-Marie-Tooth Type 1 A Drug Profile451
  Stem Cell Therapy to Activate PMP22 for Charcot-Marie-Tooth Disease Type 1A Drug Profile461
Charcot-Marie-Tooth Disease Dormant Projects471
Charcot-Marie-Tooth Disease Product Development Milestones4811
  Featured News &Press Releases481
    Apr 25, 2016: Pharnext Announces the Opening of the First U.S. Study Site for its PLEO-CMT International Pivotal Phase 3 Trial in Charcot-Marie-Tooth Disease Type 1A481
    Feb 16, 2016: Pharnext Supports the Fight Against Rare Diseases through Development of Pleotherapy-based Treatments491
    Jan 25, 2016: IFB-088 (Sephin1) receives orphan drug designation in the European Union for the treatment of Charcot-Marie-Tooth disease491
    Dec 15, 2015: Pharnext Initiates PLEO-CMT, an International Pivotal Phase 3 Trial, in Charcot-Marie-Tooth disease type 1A501
    Oct 27, 2015: FDA grants orphan drug designation to IFB-088 (Sephin1) for the treatment of Charcot-Marie-Tooth disease511
    Jun 30, 2015: Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting511
    Jan 13, 2015: InFlectis BioScience banks 1.75m to realise the potential of IFB-088 drug candidate, a breakthrough therapeutic approach to treat neurodegenerative diseases521
    Dec 17, 2014: Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A through Two Peer-Reviewed Publications521
    Oct 21, 2014: Addex And The Charcot-Marie-Tooth Association Enter Collaboration To Advance ADX71441 In Charcot-Marie-Tooth 1A disorder531
    Jun 23, 2014: The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A541
    Oct 03, 2013: Addex ADX71441 Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease551
    Apr 24, 2013: Addex Receives Approval To Initiate Phase I First In-man Clinical Study For ADX71441551
    Jan 22, 2013: Addex Receives Broad US Composition Of Matter Patent For ADX71441561
    Jan 07, 2013: Addex Therapeutics Announces Positive Data With ADX71441 In Pre-Clinical Transgenic Model Of Charcot-Marie-Tooth 1A Disease571
    Nov 22, 2011: Pharnext Completes Patient Recruitment For Phase II Study Of PXT3003 In Type 1A Charcot-Marie-Tooth Disease572
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Charcot-Marie-Tooth-Disease-Pipeline-Review-H2-2016-2088-16169>
  
APA:
Global Markets Direct - Market Research. (2016). Charcot-Marie-Tooth Disease - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Charcot-Marie-Tooth-Disease-Pipeline-Review-H2-2016-2088-16169>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.